Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) EBITDA Margin (2016 - 2025)

Seres Therapeutics' EBITDA Margin history spans 10 years, with the latest figure at 6403.7% for Q3 2025.

  • For Q3 2025, EBITDA Margin changed N/A year-over-year to 6403.7%; the TTM value through Sep 2025 reached 9311.76%, up 3049292.0%, while the annual FY2023 figure was 90.02%, 341881.0% up from the prior year.
  • EBITDA Margin for Q3 2025 was 6403.7% at Seres Therapeutics, down from 2530.26% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 53.83% in Q3 2021 and bottomed at 64450.0% in Q4 2023.
  • The 5-year median for EBITDA Margin is 3166.64% (2022), against an average of 8750.44%.
  • The largest annual shift saw EBITDA Margin tumbled -5740487bps in 2023 before it soared 6191974bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 693.42% in 2021, then plummeted by -916bps to 7045.13% in 2022, then crashed by -815bps to 64450.0% in 2023, then soared by 96bps to 2530.26% in 2024, then tumbled by -153bps to 6403.7% in 2025.
  • Per Business Quant, the three most recent readings for MCRB's EBITDA Margin are 6403.7% (Q3 2025), 2530.26% (Q4 2024), and 64450.0% (Q4 2023).